ClinicalTrials.gg
CompletedNCT00917579Updated Mar 12, 2021Results posted

Bioequivalence Study Comparing A New 10 Mg Atorvastatin Tablet To A 10 Mg Atorvastatin Commercial Tablet

A Phase 4 interventional study of Atorvastatin and Atorvastatin in Hypercholesterolemia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-12.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 77 studies testing atorvastatin in Hypercholesterolemia — 1 open to participants now, 1 under way, none of them phase 3. Atorvastatin · Hypercholesterolemia.

Enrollment
49th of 75
76 · median 148
Started
2008
with 12 others
Phase 4
28 of 77
1 open now
Registered
38th of 77
by date
Lead sponsor
10 of 77
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 77 studies testing atorvastatin in Hypercholesterolemia, this one is the 49th largest by enrollment of the 75 interventional ones that give a count, is one of 13 that started in 2008, is one of 28 in phase 4, and was the 38th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 77 studies testing atorvastatin in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About atorvastatin

Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies testing atorvastatin in Hypercholesterolemia, or all of them as a file.
02

Study summary

  • To determine whether new 10 mg atorvastatin tablets are bioequivalent to 10 mg commercial atorvastatin tablets (Lipitor®).
03

Conditions studied

  • Hypercholesterolemia

Keywords

  • Bioequivalence, pharmacokinetics, atorvastatin
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and/or female subjects between the ages of 18 and 55 years
  • (BMI) of 18 to 30 kg/m2; and a total body weight >50 kg (110 lbs).

Exclusion criteria

Exclusion Criteria:

  • Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing) disease or clinical findings at screening.
  • Treatment with an drug within 30 days or 5 half lives preceding the first dose of study medication.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
76 participants (actual)

Study arms

  • Other
    Reference

    10 mg atorvastatin

    Drug: Atorvastatin

  • Experimental
    Test

    New 10 mg atorvastatin tablet

    Drug: Atorvastatin

Interventions

  • A single 10 mg dose of marketed 10 mg atorvastatin tablets

  • A single 10 mg dose of new formulation of 10 mg atorvastatin

06

What researchers measure

Primary outcomes

  1. Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC Infinity)

    AUCinf = Area under the plasma concentration-time curve from time 0 (predose) extrapolated to infinite time; measured in nanograms times hour per milliliter (ng•hr/mL).

    Time frame: 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 10, 12, 24, 36, 48, 72 hours post dose

  2. Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)

    AUClast = area under the plasma concentration-time curve from 0 (predose) to the time of the last measureable concentration (Clast); measured in nanograms times hour per milliliter (ng•hr/mL).

    Time frame: 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 10, 12, 24, 36, 48, 72 hours post dose

  3. Maximum Observed Plasma Concentration (Cmax)

    Cmax = maximum observed plasma concentration. Measured in nanograms per milliter (ng/mL).

    Time frame: 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 10, 12, 24, 36, 48, 72 hours post dose

Secondary outcomes

  1. Time to Reach Maximum Plasma Concentration (Tmax)

    Tmax = time (hours) to maximum plasma concentration (Cmax).

    Time frame: 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 10, 12, 24, 36, 48, 72 hours post dose

  2. Plasma Elimination Half-life (t1/2)

    t1/2 = terminal elimination half-life in hours.

    Time frame: 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 10, 12, 24, 36, 48, 72 hours post dose

07

Results

Posted Oct 14, 2009

Participant flow

Healthy volunteers were recruited from one research center between July 2008 and September 2008.

Period 1: 1st Intervention
Participant flow — Period 1: 1st Intervention
MilestoneTest Drug First, Then Reference DrugReference Drug First, Then Test Drug
Started3937
Completed3937
Not completed00
Washout >= 2 Weeks
Participant flow — Washout >= 2 Weeks
MilestoneTest Drug First, Then Reference DrugReference Drug First, Then Test Drug
Started3937
Completed3737
Not completed20
Withdrew: Adverse event10
Withdrew: Withdrawal by subject10
Period 2: 2nd Intervention
Participant flow — Period 2: 2nd Intervention
MilestoneTest Drug First, Then Reference DrugReference Drug First, Then Test Drug
Started3737
Completed3737
Not completed00

Outcome measures

PrimaryArea Under the Curve From Time Zero to Extrapolated Infinite Time (AUC Infinity)

AUCinf = Area under the plasma concentration-time curve from time 0 (predose) extrapolated to infinite time; measured in nanograms times hour per milliliter (ng•hr/mL).

Time frame:
0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 10, 12, 24, 36, 48, 72 hours post dose
Reported as:
Mean · ng•hr/mL
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC Infinity)
ng•hr/mLTest DrugReference Drug
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUC Infinity)18.3206 ± 8.2645419.2583 ± 8.79739
Statistical analysis
  • Test Drug vs Reference Drug · ANOVA · Ratio of adjusted geometric means: 95.34 · 90% CI 91.33 to 99.52Parameter estimate = ratio (%) (test/reference) of adjusted geometric means. AUClast + (Clast\*/kel), where Clast\* was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis.
PrimaryArea Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)

AUClast = area under the plasma concentration-time curve from 0 (predose) to the time of the last measureable concentration (Clast); measured in nanograms times hour per milliliter (ng•hr/mL).

Time frame:
0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 10, 12, 24, 36, 48, 72 hours post dose
Reported as:
Mean · ng•hr/mL
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)
ng•hr/mLTest DrugReference Drug
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)15.7382 ± 7.8892016.5452 ± 8.71551
Statistical analysis
  • Test Drug vs Reference Drug · ANOVA · Ratio of adjusted geometric means: 95.79 · 90% CI 91.07 to 100.76Parameter estimate = ratio (%) (test/reference) of adjusted geometric means. Log-linear trapezoidal method.
PrimaryMaximum Observed Plasma Concentration (Cmax)

Cmax = maximum observed plasma concentration. Measured in nanograms per milliter (ng/mL).

Time frame:
0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 10, 12, 24, 36, 48, 72 hours post dose
Reported as:
Mean · ng/mL
Maximum Observed Plasma Concentration (Cmax)
ng/mLTest DrugReference Drug
Maximum Observed Plasma Concentration (Cmax)2.6594 ± 1.446172.8086 ± 1.23048
Statistical analysis
  • Test Drug vs Reference Drug · ANOVA · Ratio of adjusted geometric means: 91.41 · 90% CI 83.39 to 100.20Parameter estimate = ratio (%) (test/reference) of adjusted geometric means.
SecondaryTime to Reach Maximum Plasma Concentration (Tmax)

Tmax = time (hours) to maximum plasma concentration (Cmax).

Time frame:
0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 10, 12, 24, 36, 48, 72 hours post dose
Reported as:
Median · hours
Time to Reach Maximum Plasma Concentration (Tmax)
hoursTest DrugReference Drug
Time to Reach Maximum Plasma Concentration (Tmax)1.000 (0.250 to 9.000)0.5000 (0.250 to 4.000)
SecondaryPlasma Elimination Half-life (t1/2)

t1/2 = terminal elimination half-life in hours.

Time frame:
0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 10, 12, 24, 36, 48, 72 hours post dose
Reported as:
Mean · hours
Plasma Elimination Half-life (t1/2)
hoursTest DrugReference Drug
Plasma Elimination Half-life (t1/2)10.39 ± 4.001810.78 ± 3.9640

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Test Drug———
Reference Drug———
Most frequent serious events
Most frequent serious events
EventTest DrugReference Drug
Renal colicRenal and urinary disorders1/760/74
Most frequent other events
Showing 10 of 12
Most frequent other events
EventTest DrugReference Drug
HeadacheNervous system disorders1/766/74
ConstipationGastrointestinal disorders1/764/74
NauseaGastrointestinal disorders0/762/74
Syncope vasovagalNervous system disorders0/762/74
Pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders0/762/74
DyspepsiaGastrointestinal disorders0/761/74
VomitingGastrointestinal disorders0/761/74
DizzinessNervous system disorders1/761/74
SyncopeNervous system disorders0/761/74
AnxietyPsychiatric disorders0/761/74

Baseline characteristics

Age, Customized
Age, Customized(participants)Total Number of Participants
18-44 years59
45-64 years17
Sex: Female, Male
Sex: Female, Male(Participants)Total Number of Participants
Female38
Male38
08

Study locations

1 site
  • Pfizer Investigational Site
    Miami, Florida 33169, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2008, a primary completion of Sep 2008 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2009, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2009
First posted
Jun 10, 2009
Start
Jul 2008
Primary completionActual
Sep 2008
CompletionActual
Sep 2008
Results first posted
Oct 14, 2009
Last update
Mar 12, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00917579
Responsible party
Sponsor
First posted
Jun 10, 2009
Start date
Jul 2008
Primary completion
Sep 2008
Completion
Sep 2008
Results posted
Oct 14, 2009
Last update
Mar 12, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atorvastatin

Start the discussion